Page 1 (0s)
1. Executive Summary(HEME). Strategy Priorities. Expand Rituximab market share with SC expansion & oncologists penetration Strengthen the capabilities of TAEs to make evidence based clinical decision in contrast to the competitors HCPs to aware with high unmet need for R/R DLBCL patients..
Page 2 (1m 15s)
2024 Expense(HEME). Congress and Preceptorship Name of Congress : EHA (13th-16th June)(F2F) Number of HCPs : 1 Expense Expected : 15,000,000 MMK.